We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
BeiGene Ltd. (BGNE) said it agreed with Celgene Corp. (CELG) to terminate the parties' global collaboration for tislelizumab in advance of the pending acquisition of Celgene by Bristol-Myers Squibb (BMY).
Commercial-stage biopharmaceutical company BeiGene said Celgene agreed to pay it $150 million. Tislelizumab is BeiGene's investigational anti-PD-1 antibody
Tislelizumab has been dosed in over 2,950 patients globally. With two new drug applications under review in China, BeiGene said it expects tislelizumab to receive its first regulatory approval later this year.
"Our collaboration with Celgene was instrumental for the late-stage clinical development of tislelizumab and has provided us with significant resources to continue our broad clinical program," said Chief Executive John V. Oyler.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
June 17, 2019 07:58 ET (11:58 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
